Sign in

You're signed outSign in or to get full access.

Ashleigh Acker

Ashleigh Acker

Biotechnology Equity Research Associate at Piper Sandler & Co.

Chicago, IL, US

Ashleigh Acker is a Biotechnology Equity Research Associate at Piper Sandler Companies, specializing in biotechnology sector analysis and supporting senior analysts in covering innovative biotech firms. She began her role at Piper Sandler less than a year ago, following analytical and business development positions at organizations such as BioHealth Innovation. While at Piper Sandler, she focuses on in-depth research into emerging biotech companies, although coverage of specific firms and quantitative performance data are not yet widely published given her recent entry into equity research. Ashleigh holds a business analysis background and is building her credentials in financial services as she advances her research career.

Ashleigh Acker's questions to ARDELYX (ARDX) leadership

Question · Q2 2025

Ashleigh Acker, on for Allison Pratzel of Piper Sandler, asked what specific metrics for Xphozah would provide the confidence to issue guidance. She also inquired about expectations for licensing and product supply revenue in the second half of the year.

Answer

CEO Mike Raab indicated that seeing "more of the same" consistent performance from Xphozah would be the trigger for providing guidance. CFO Justin Renz projected that product supply revenue from partners would be limited in Q3 but expects an order in Q4 comparable to Q2's $6 million, noting that partner orders are not consistently quarterly.

Ask follow-up questions

Fintool

Fintool can predict ARDELYX logo ARDX's earnings beat/miss a week before the call